303 related articles for article (PubMed ID: 17079850)
1. [Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis].
Suzuki Y
Clin Calcium; 2006 Nov; 16(11):1834-42. PubMed ID: 17079850
[TBL] [Abstract][Full Text] [Related]
2. [Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Sato S
Clin Calcium; 2007 Apr; 17(4):600-5. PubMed ID: 17404491
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid-induced osteoporosis: hope on the HORIZON.
Gennari L; Bilezikian JP
Lancet; 2009 Apr; 373(9671):1225-6. PubMed ID: 19362657
[No Abstract] [Full Text] [Related]
4. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
[TBL] [Abstract][Full Text] [Related]
5. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
Orcel P
Joint Bone Spine; 2005 Dec; 72(6):461-5. PubMed ID: 16326129
[TBL] [Abstract][Full Text] [Related]
8. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
[TBL] [Abstract][Full Text] [Related]
9. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Iwamoto J; Takeda T; Sato Y
Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates. A cornerstone of osteoporosis treatment.
Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
[No Abstract] [Full Text] [Related]
11. Is the increase in osteoporosis prevention a result of the audit?
Naunton M
Clin Neurol Neurosurg; 2006 Oct; 108(7):718-9. PubMed ID: 16621242
[No Abstract] [Full Text] [Related]
12. [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
Suzuki Y; Sato S
Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275
[TBL] [Abstract][Full Text] [Related]
13. Prevention of glucocorticoid-induced osteoporosis.
Saag KG
South Med J; 2004 Jun; 97(6):555-8. PubMed ID: 15255421
[TBL] [Abstract][Full Text] [Related]
14. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
Soen S
Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
[TBL] [Abstract][Full Text] [Related]
15. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases.
Cowan S; Morin S; Ernst P
Thorax; 1998 May; 53(5):331-2. PubMed ID: 9708219
[No Abstract] [Full Text] [Related]
17. Prevention and treatment of glucocorticoid-induced osteoporosis.
Curtis JR; Saag KG
Curr Osteoporos Rep; 2007 Mar; 5(1):14-21. PubMed ID: 17320023
[TBL] [Abstract][Full Text] [Related]
18. [Management of glucocorticoid-induced osteoporosis in childhood].
Tanaka H
Clin Calcium; 2006 Nov; 16(11):1879-86. PubMed ID: 17079856
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-induced osteoporosis: treatment options and guidelines.
Maricic M
Curr Osteoporos Rep; 2005 Mar; 3(1):25-9. PubMed ID: 16036098
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
